CAPRICOR THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
CAPR$9.85+9.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
DECEMBER 31, 2025 AND 2024
| | | | | | | |
|---|---|---|---|---|---|---|
| | ||||||
| ASSETS | ||||||
| | | | | | | |
| · · · · | ||||||
| · · December 31, 2025 · · December 31, 2024 | ||||||
| | | | | | | |
| CURRENT ASSETS | | | | | | |
| Cash and cash equivalents | | $287,847,312 | | $11,286,996 | ||
| Marketable securities | | 30,281,603 | | 140,228,881 | ||
| Receivables | | 59,167 | | 10,368,489 | ||
| Prepaid expenses and other current assets | | 4,751,674 | | 1,500,901 | ||
| | | | | | | |
| TOTAL CURRENT ASSETS | | 322,939,756 | | 163,385,267 | ||
| | | | | | | |
| PROPERTY AND EQUIPMENT, net | | 18,312,238 | | 5,561,597 | ||
| | | | | | | |
| OTHER ASSETS | | | | | ||
| Lease right-of-use assets, net | | | 13,537,820 | | | 1,312,522 |
| Other assets | | 1,159,480 | | 221,700 | ||
| | | | | | | |
| TOTAL ASSETS | | $355,949,294 | | $170,481,086 | ||
| | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
| | | | | | | |
| CURRENT LIABILITIES | | | | | ||
| Accounts payable | | $1,654,754 | | $3,283,712 | ||
| Accrued expenses | | | 15,557,646 | | | 4,907,665 |
| Lease liabilities, current | | | 202,376 | | | 834,799 |
| CIRM liability, current | | | 6,421,984 | | | — |
| Deferred revenue, current | | | 12,000,000 | | | 12,000,000 |
| | | | | | | |
| TOTAL CURRENT LIABILITIES | | 35,836,760 | | 21,026,176 | ||
| | | | | | | |
| LONG-TERM LIABILITIES | | | | | ||
| CIRM liability, net of current | | | — | | | 3,376,259 |
| Lease liabilities, net of current | | | 14,320,389 | | | 616,315 |
| | | | | | | |
| TOTAL LONG-TERM LIABILITIES | | 14,320,389 | | 3,992,574 | ||
| | | | | | | |
| TOTAL LIABILITIES | | 50,157,149 | | 25,018,750 | ||
| | | | | | | |
| COMMITMENTS AND CONTINGENCIES (NOTE 15) | | | | | ||
| | | | | | | |
| STOCKHOLDERS’ EQUITY | | | | | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding | | — | | — | ||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 57,370,909 and 45,582,288 shares issued and outstanding, respectively | | 57,371 | | 45,582 | ||
| Additional paid-in capital | | 610,330,105 | | 344,224,338 | ||
| Accumulated other comprehensive income | | 283,154 | | 1,026,955 | ||
| Accumulated deficit | | (304,878,485) | | (199,834,539) | ||
| | | | | | | |
| TOTAL STOCKHOLDERS’ EQUITY | | 305,792,145 | | 145,462,336 | ||
| | | | | | | |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | | $355,949,294 | | $170,481,086 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.